Prevalence of HIV, Syphilis, Hepatitis B, and Hepatitis C among Entrants to Maryland Correctional Facilities

Journal of Urban Health

Volumn 81, Issue 1, 2004, Pages 25-37

  Solomon, Liza ^a,c   Flynn, Colin ^a   Muck, Kelly ^a   Vertefeuille, John ^b  

^a AIDS Administration   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NONE   (United States)

Author keywords

Hepatitis B virus; Hepatitis C virus; Human immunodeficiency virus; Jail; Prison; Seroprevalence; Syphilis

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ADULT; AGE; ALGORITHM; ARTICLE; CAUCASIAN; COMORBIDITY; DETENTION; FEMALE; GENDER; HEALTH CARE COST; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PRISON; PUBLIC HEALTH; RISK FACTOR; SEROCONVERSION; SEROPREVALENCE; SYPHILIS; UNITED STATES; VIRUS INFECTION;

ADOLESCENT; ADULT; COMORBIDITY; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MARYLAND; MIDDLE AGED; PRISONS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SYPHILIS;

EID: 2442424053     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jth085     Document Type: Article

References (18)

1. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2003;92:1789-1794.
2. Charuvasttra A, Stein J, Schwartzapeel B, et al. Hepatitis B vaccination practices in state and federal prisons. Public Healtb Rep. 2001;116:203-208.
3. Allen S. Developing a systematic approach to hepatitis C for correctional systems: controversies and emerging consensus. HEPP News. 2003;6(4):1-4.
4. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42-48.
5. Weinbaum C, Lyerla R, Margolis H. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Morb Mortal Wkly Rep. 2003;52(RR-1):1-36.
6. Macalino GE, Rich JD, Sanford-Colby S, Vlahov D. Intake prevalence and intraprison incidence of HIV, hepatitis B (HBV) and hepatitis C (HCV) among sentenced inmates in Rhode Island. International Conference AIDS. July 7-12, 2002; Barcelona, Spain.
7. Vlahov D, Brewer F, Castro KG, et al. Prevalence of antibody to HIV-1 among entrants to US correctional facilities. JAMA. 1991;265:1129-1132.
8. Vlahov D, Munoz A, Brewer F, Taylor E, Canner C, Polk BF. Seasonal and annual variation of antibody to HIV-1 among male inmates entering Maryland prisons: update. AIDS. 1990;4:345-350.
9. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655-661.
10. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine. 1995;74:212-220.
11. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection host, viral and environmental factors. JAMA. 2000;284:450-456.
12. Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr. 2003;33:356-364.
13. Maruschak LM. HIV in Prisons, 2000. Washington, DC: Bureau of Justice Statistics, US Dept of Justice; 2002. Publication NCJ-196023.
14. Behrendt C, Kendig N, Dambita C, Horman J, Lawlor J, Vlahov D. Voluntary testing for human immunodeficiency virus (HIV) in a prison population with a high prevalence of HIV. Am J Epidemiol. 1994;139:918-926.
15. Vlahov D, Brewer F, Munoz A, Hall D, Taylor E, Polk BF. Temporal trends of human immunodeficiency virus type 1 (HIV-1) infection among inmates entering a statewide prison system, 1985-1987. J Acquir Immune Defic Syndr. 1989;2:283-290.
16. Nerenberg RWM, De Groot A. HCV in corrections: frontline or backwater? HEPP News. 2002;5(4):1-2.
17. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect. Dis. 2001;32:492-497.
18. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138:187-190.